EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study

Yaofei Jiang, Jie Wu, Shuhui Dong, Zhenyu Zhang, Weixin Bei, Lisheng Zheng, Yanqun Xiang, Guoying Liu

Cancer Immunology, Immunotherapy · 2026

DOI: 10.1007/s00262-025-04258-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Yaofei Jiang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, NanChang, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Clinical Research Training Project of The First Affiliated Hospital of Nanchang University, the Science and Technology Project of Health Commission of Jiangxi Provincial.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immune checkpoint inhibitor (ICI) rechallenge in recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) is a promising therapeutic strategy. We aim to assess its treatment outcomes and build prognostic models for clinical practice. METHODS: R/M NPC patients who failed prior anti-PD-1 immunotherapy and received ICI rechallenge were enrolled. Clinical features were recorded, and univariate and multivariate analysis was conducted to evaluate prognostic factors. Prognostic models were developed and validated to predict progression-free survival (PFS) and overall survival (OS), respectively. RESULTS: A total of 243 patients were enrolled between January 2019 and December 2023. The objective response rate (ORR) and disease control rate (DCR) for the entire cohort were 24.3% and 75.7%, respectively. After a median follow-up of 10.5 months, the median PFS was 6.3 months, the median duration of response (DOR) was 9.8 months, and the median OS was 19.8 months. Multivariate Cox analysis identified that the latest efficacy of anti-PD-1 therapy (HR 0.587, 95%CI 0.357-0.963, p = 0.035), EBV DNA level (HR 1.743, 95%CI 1.252-2.426, p = 0.001), locoregional therapy (HR 0.467, 95%CI 0.268-0.812, p = 0.007), and rechallenge with anti-PD-1 inhibitor (HR 1.548, 95%CI 1.005-2.385, p = 0.047) were independent statistically prognostic factors for PFS. Additionally, age (HR 2.044, 95%CI 1.297-3.222, p = 0.002), bone metastatic (HR 1.642, 95%CI 1.055-2.555, p = 0.028), and EBV DNA level (HR 1.673, 95%CI 1.034-2.706, p = 0.036) were independent significantly associated with OS. Prognostic models were developed based on the risk factors. Stratification of patients by the prognostic scores from these models showed that the low-risk group patients had significantly improved PFS and OS compared to their high-risk counterparts. CONCLUSIONS: This study provided a comprehensive assessment of the efficacy and prognostic factors of ICI rechallenge in RM-NPC patients who failed prior anti-PD-1 immunotherapy, and developed a prognostic model which could identify candidates for ICI rechallenge. Further prospective trials are warranted to confirm and expand these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNasopharyngeal CarcinomaNasopharyngeal NeoplasmsNeoplasm Recurrence, LocalHumansFemalePrognosisMaleMiddle AgedAdultAgedRetrospective StudiesRetreatmentNeoplasm Metastasis

Stichwörter der Autor:innen

Anti-PD-1 immunotherapyEfficacyICI rechallengeNasopharyngeal carcinomaPrognostic model

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, NanChang, China.
  • Departments of Cancer Research Institute, Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute and Xiangya School of Basic Medicine Sciences, Affiliated Ca…
  • Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
  • Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Canc…
  • Department of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China. zhenglisheng@gdph.org.cn.
  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Department of Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. liugy0109…

Förderung

  • National Natural Science Foundation of China
  • Clinical Research Training Project of The First Affiliated Hospital of Nanchang University
  • the Science and Technology Project of Health Commission of Jiangxi Provincial
  • Natural Science Foundation of Xinjiang Province of China

Zitieren

APA

Jiang, Y., Wu, J., Dong, S., Zhang, Z., Bei, W., Zheng, L., Xiang, Y., & Liu, G. (2026). Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04258-y

Vancouver

Jiang Y, Wu J, Dong S, Zhang Z, Bei W, Zheng L, et al. Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-025-04258-y

BibTeX
@article{Jiang2026,
  author = {Jiang, Yaofei and Wu, Jie and Dong, Shuhui and Zhang, Zhenyu and Bei, Weixin and Zheng, Lisheng and Xiang, Yanqun and Liu, Guoying},
  title = {Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-025-04258-y}
}
Kostenlos starten →